169 related articles for article (PubMed ID: 16789756)
1. New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.
Ballet S; Salvadori S; Trapella C; Bryant SD; Jinsmaa Y; Lazarus LH; Negri L; Giannini E; Lattanzi R; Tourwé D; Balboni G
J Med Chem; 2006 Jun; 49(13):3990-3. PubMed ID: 16789756
[TBL] [Abstract][Full Text] [Related]
2. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Balboni G; Onnis V; Congiu C; Zotti M; Sasaki Y; Ambo A; Bryant SD; Jinsmaa Y; Lazarus LH; Trapella C; Salvadori S
J Med Chem; 2006 Sep; 49(18):5610-7. PubMed ID: 16942034
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
[TBL] [Abstract][Full Text] [Related]
4. Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore.
Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Jinsmaa Y; Bryant SD; Lazarus LH
J Med Chem; 2002 Dec; 45(25):5556-63. PubMed ID: 12459023
[TBL] [Abstract][Full Text] [Related]
5. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
[TBL] [Abstract][Full Text] [Related]
6. Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Li T; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Lazarus LH; Okada Y
J Med Chem; 2007 Jun; 50(12):2753-66. PubMed ID: 17497839
[TBL] [Abstract][Full Text] [Related]
7. Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Balboni G; Fiorini S; Baldisserotto A; Trapella C; Sasaki Y; Ambo A; Marczak ED; Lazarus LH; Salvadori S
J Med Chem; 2008 Aug; 51(16):5109-17. PubMed ID: 18680274
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NH₂ using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold.
De Wachter R; de Graaf C; Keresztes A; Vandormael B; Ballet S; Tóth G; Rognan D; Tourwé D
J Med Chem; 2011 Oct; 54(19):6538-47. PubMed ID: 21870874
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
10. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y
J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927
[TBL] [Abstract][Full Text] [Related]
11. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.
Salvadori S; Attila M; Balboni G; Bianchi C; Bryant SD; Crescenzi O; Guerrini R; Picone D; Tancredi T; Temussi PA
Mol Med; 1995 Sep; 1(6):678-89. PubMed ID: 8529134
[TBL] [Abstract][Full Text] [Related]
12. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.
Salvadori S; Guerrini R; Balboni G; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1999 Dec; 42(24):5010-9. PubMed ID: 10585210
[TBL] [Abstract][Full Text] [Related]
13. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
Fujita Y; Tsuda Y; Li T; Motoyama T; Takahashi M; Shimizu Y; Yokoi T; Sasaki Y; Ambo A; Kita A; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
J Med Chem; 2004 Jul; 47(14):3591-9. PubMed ID: 15214786
[TBL] [Abstract][Full Text] [Related]
14. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.
Li T; Fujita Y; Tsuda Y; Miyazaki A; Ambo A; Sasaki Y; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
J Med Chem; 2005 Jan; 48(2):586-92. PubMed ID: 15658871
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism.
Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
Bioorg Med Chem; 2003 Dec; 11(24):5435-41. PubMed ID: 14642588
[TBL] [Abstract][Full Text] [Related]
16. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162
[TBL] [Abstract][Full Text] [Related]
17. Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.
Balboni G; Marzola E; Sasaki Y; Ambo A; Marczak ED; Lazarus LH; Salvadori S
Bioorg Med Chem; 2010 Aug; 18(16):6024-30. PubMed ID: 20637637
[TBL] [Abstract][Full Text] [Related]
18. Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold.
Ballet S; Feytens D; Wachter RD; Vlaeminck MD; Marczak ED; Salvadori S; Graaf Cd; Rognan D; Negri L; Lattanzi R; Lazarus LH; Tourwé D; Balboni G
Bioorg Med Chem Lett; 2009 Jan; 19(2):433-7. PubMed ID: 19062273
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of opioidmimetics, 3-[H-Dmt-NH(CH(2))(m)]-6-[H-Dmt-NH(CH(2))(n)]-2(1H)-pyrazinones, and studies on structure-activity relationships.
Shiotani K; Miyazaki A; Li T; Tsuda Y; Yokoi T; Ambo A; Sasaki Y; Bryant SD; Jinsmaa Y; Lazarus LH; Okada Y
Med Chem; 2007 Nov; 3(6):583-98. PubMed ID: 18045209
[TBL] [Abstract][Full Text] [Related]
20. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
